Acute Lymphoblastic Leukemia Xplained
Hi, I’m Charles. Back in 2015 I woke up one night with really terrible back pain. I couldn’t stand, then I couldn’t lay down or sit down – I just couldn’t get comfortable. It happened a couple of times, and finally some scans and a blood test showed I had ALL. From there everything went lightening quick – straight upstairs for chemo. I’ve had lots of treatments and have learnt a lot. I hope my story can help you understand more. Check out the video to hear more from me.
Medicine X Story
Working as a medical doctor, I realized that far too many patients are confused about their diagnoses, their conditions, and their treatments. There’s a disconnect between the language that doctors use and what everyday people understand. This can make you feel incredibly hopeless and anxious at an often very difficult time in your life.
We believe there is a better way. We believe all patients – regardless of age, gender, culture or condition – should have access to medical information they can understand! Everyone should feel informed and empowered in order to engage with their doctors and be involved in making medical decisions.
This is why Medicine X was created.
Dr. Kim Chilman-Blair
Founder, Medicine X
About ALL Xplained
The ALL Xplained story is based on a real person – Charles! It reflects his story, his experiences, and his advice to others. There have also been lots of people who contributed along the way with their stories and advice. Thanks to everyone who helped create ALL Xplained!
The Medicine X team are doctors, artists, and creative writers who all work to make sure of one thing — the information is easy to understand. No more medical jargon! Everything is correct and up-to-date!
Each of the stories we create is different, so there are experts in the field that have reviewed the story to ensure it is spot-on in terms of medical information. These experts are professionals in medical bodies and institutions.
Share your thoughts!
We’d Love to Hear Your Thoughts About ALL Xplained
Check out the star-studded line up of experts that have been involved with Acute Lymphoblastic Leukemia Xplained!
Meet the Creators
Meet the artist and story writer behind Acute Lymphoblastic Leukemia Xplained!
Josep R. is a Spanish illustrator. Interested in the Franco-Belgian comics and modern illustration, he studied illustration at the art school of Alcoi. Since then he has worked on comic books and magazines. He began collaborating with Medicine X because he believes in the power of illustration and art. He feels Medicine X offers great programs that can help patients understand their medical conditions in the best (and most engaging) way.
Shawn deLoache is a Los Angeles based writer for TV, Film, digital, and comics. He’s written everything from gut-wrenching dramas to supernatural comedies, and yet he says “I’ve found nothing has the same impact as working with Medicine X. I’ve always thought of stories as a gift. Normally that gift is entertainment, but with Medicine X it’s so much more. With Medicine X the stories we’re telling, I’m telling, aren’t just a gift of entertainment (though I hope they entertain), but of knowledge, of support, of helping people understand their illness and know that they’re not alone. It’s the kind of writing that makes me feel like I’m making a difference, and for that, I am very humbled, proud, and grateful to be a part of the Medicine X family.”
Kindly supported by
Kindly supported by
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.